Articles tagged "Immunosuppression"

2019 American Transplant Congress
Clinical Trial of Allogeneic Islet Transplantation in the Treatment of Diabetes after Renal Transplantation
W. liang, M. Hu, G. Peng, D. Zhou, C. Zeng, W. Zhou, q. Ye, Z. Wang
Zhongnan Hospital of Wuhan University, Institute of Hepatobiliary Diseases, Wuhan, China
*Purpose: Diabetes after renal transplantation is one of the most serious complications after renal transplantation. It has a serious impact to the survival of kidney…
2019 American Transplant Congress
What’s in a High Dose? An Analysis of Tacrolimus Pharmacokinetic Parameters in Rapid Metabolizers
P. West-Thielke¹, A. Maldonado², S. J. Patel³, D. R. Stevens³, U. Meier-Kriesche³, D. Brennan⁴
¹University of Illinois, Chicago, Chicago, IL, ²Vidant Medical Center, Greenville, NC, ³Veloxis Pharmaceuticals Inc., Cary, NC, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
*Purpose: CYP3A5*1 expressers exhibit differences in immediate-release tacrolimus (IR-Tac) PK and require higher doses of IR-Tac to maintain therapeutic trough concentrations. LCP-Tacrolimus (LCPT) demonstrates a…
2019 American Transplant Congress
Tocilizumab for Refractory Antibody-Mediated Rejection in Pediatric Kidney Transplantation
A. Dokras, C. Butler, Q. Zhang, E. Reed, R. Ettenger, P. Weng, M. Pearl
University of California, Los Angeles, Los Angeles, CA
*Purpose: IL-6 blockade may play a role in reducing human leukocyte antigen donor specific antibodies (HLA DSA) production and stabilizing allograft function. We aimed to…
2019 American Transplant Congress
Hephaistos Study Outcome on Renal Function after 12 Month Everolimus Plus Reduced Tacrolimus in De Novo Liver Transplant Recipients versus Standard Tacrolimus
F. Braun¹, P. Schemmer¹, H. Schlitt¹, A. Pascher¹, C. Klein¹, U. Neumann¹, I. Kroeger², P. Wimmer², B. Nashan¹
¹Study Group, Hephaistos, Germany, ²Novartis Pharma GmbH, Nuernberg, Germany
*Purpose: The HEPHAISTOS study was designed to compare efficacy and safety of earlyuse of everolimus [EVR] combined with reduced tacrolimus [rTAC] versus Standard tacrolimus [TAC-C)…
2019 American Transplant Congress
Oral Preconditioning of Donors after Brain Death with Calcineurin Inhibitors vs. Inhibitors of Mammalian Target for Rapamycin in Pig Kidney Transplantation
S. Abbasi Dezfouli¹, M. Golriz¹, O. Ghamarnejad¹, E. Khajeh¹, S. Mohammadi¹, M. Nikdad¹, A. Majlesara¹, M. Sabagh¹, P. Fathi¹, S. Shafiei¹, M. Kentar², A. Younsi², C. Eckert³, T. Poth³, A. Mehrabi¹, A. Nickkholgh¹
¹Department of General, Visceral, and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany, ²Department of Neurosurgery, University of Heidelberg, Heidelberg, Germany, ³Department of Pathology, University of Heidelberg, Heidelberg, Germany
*Purpose: The systemic inflammatory cascade triggered in donors after brain death (DBD) enhances the ischemia-reperfusion injury (IRI) after organ transplantation. Data regarding donor preconditioning with…
2019 American Transplant Congress
Evaluation of Envarsus XR in African American Kidney Transplant Recipients
L. R. Lineberger¹, E. Hollinger², N. Kenyon¹, M. Brokohf¹, N. Alvey¹
¹Pharmacy, Rush University Medical Center, Chicago, IL, ²Rush University Medical Center, Chicago, IL
*Purpose: This study is being conducted to evaluate the clinical impact of the utilization of tacrolimus LCP (TAC-LCP) compared to tacrolimus immediate release (TAC-IR) in…
2019 American Transplant Congress
Long-Term Outcomes of Early Conversion to Sirolimus-Based Immunosuppression in Children with Living Donor Kidney Transplants
B. Stotter¹, S. Lui¹, E. Weller², L. Ganapathi¹, M. Ferguson¹, A. Traum¹, M. Somers¹, N. Rodig¹
¹Pediatrics, Boston Children's Hospital, Boston, MA, ²Biostatistics and Research Design Center, Boston Children's Hospital, Boston, MA
*Purpose: Following kidney transplantation (KTx), calcineurin inhibitor (CNI)-based maintenance immunosuppression (IS) can be associated with nephrotoxicity and other complications including viral infections and malignancy. Mammalian…
2019 American Transplant Congress
Impact of Protease Inhibitor-Based Anti-Retroviral Therapy on Tacrolimus Intrapatient Variability in HIV+ Kidney Transplant Recipients
M. H. Cooper, I. E. Dunne, S. A. Kuten, A. E. Cantwell, E. A. Graviss, D. T. Nguyen, M. J. Hobeika, A. O. Gaber
Houston Methodist Hospital, Houston, TX
*Purpose: High tacrolimus (FK) intra-patient variability (IPV) has been associated with inferior outcomes in solid organ transplantation. HIV+ transplant recipients have been shown to experience…
2019 American Transplant Congress
Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
J. Arreola Guerra¹, R. Reyes Acevedo², A. Chew Wong¹, F. Haro Alcalde¹, L. Zuñiga Macias¹, R. Delgadillo Castañeda², R. Villafan³
¹Internal Medicine and Nephrology, Centenario Hospital Miguel Hidalgo, Aguascalientes, Mexico, ²Transplantation, Centenario Hospital Miguel Hidalgo, Aguascalientes, Mexico, ³Universidad Autonoma de Aguascalientes, Aguascalientes, Mexico
*Purpose: Tacrolimus (TAC) is part of the immunosuppression scheme of more than 95% of patients after kidney transplantation in Mexico. Low TAC tacrolimus trough levels…
2019 American Transplant Congress
Donor Derived Neoplasia: Will It Be a Risk after Clinical Pig Organ Xenotransplantation?
A. Jagdale¹, H. Iwase¹, E. Klein², D. Cooper¹
¹Surgery, University of Alabama at Birmingham, Birmingham, AL, ²Surgery, University of Pittsburgh, Pittsburgh, PA
*Purpose: The survival of the nonhuman primates with life-supporting pig kidney grafts has increased substantially (to >1 year). As clinical pig organ xenotransplantation draws closer,…